CompletedPhase 2

Midodrine Effect on the Mortality Rates in Septic Shock Patients

Egypt100 participantsStarted 2022-11-07

Plain-language summary

Assessing the safety and efficacy of the adjunctive use of midodrine as a vasopressor in septic shock patients by measuring the difference in the mortality rates between control and intervention groups.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult aged 18 years or older diagnosed with septic shock. * Hypotensive and require IV vasopressor for more than 24 hours. Exclusion Criteria: * Hypovolemic shock. * Severe organic heart disease (ejection fraction \<30 percent). * Bradycardia (HR\<50 b/m). * Chronic kidney disease (serum creatinine \>2mg/dl). * Thyrotoxicosis. * Pheochromocytoma. * Known allergy to midodrine. * Unable to administer an oral medication.

What they're measuring

Mortality rates

Timeframe: Time Frame: Starting from date of randomization till shock reversal or date of death from any cause, whichever came first,assessed up to 30 days

Trial details

NCT IDNCT05778838

SponsorNoha Mansour

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-12-22

View on ClinicalTrials.gov More Septic Shock trials